Download PDFPDF
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Response to Hjardem Elisabeth, et al article Ann Rheum Dis 2007; 66: 1184-1189
    • Paul Emery, Professor
    • Other Contributors:
      • Maya H. Buch, Sarah J. Bingham and Paul Emery

    To the editor,

    We read with interest the article by Hjardem E et al which reported the experiences of switching between TNF-antagonists from the Danish patient registry, DANIBO. We would like to draw the authors’ attention to data published from our group 2 years ago which both highlights some aspects relevant to the current report and which provides some insights into the mechanisms involved. Non-response is seen...

    Show More
    Conflict of Interest:
    None declared.